adamantane has been researched along with oxidopamine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Britton, DR; DeNinno, MP; Jenner, P; Kebabian, JW; Perner, R; Schoenleber, R; Smith, L; Williams, M | 1 |
| Huang, NY; Kostrzewa, RM | 1 |
| Andrén, PE; Ekesbo, A; Gunne, LM; Sonesson, C; Tedroff, J | 1 |
| Chesselet, MF; Mehta, A; Thermos, K | 1 |
| Artusi, R; Caselli, G; Lanza, M; Makovec, F; Michotte, Y; Sarre, S | 1 |
| Cenci, MA; Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA | 2 |
| Gittis, A | 1 |
| Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Bassani, TB; Souza, LC; Turnes, JM; Vital, MABF | 1 |
11 other study(ies) available for adamantane and oxidopamine
| Article | Year |
|---|---|
A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adamantane; Administration, Oral; Animals; Antiparkinson Agents; Benzazepines; Benzopyrans; Binding Sites; Callithrix; Cell Line; Dopamine Agents; Fishes; Injections, Subcutaneous; Mice; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Receptors, Dopamine D1 | 1992 |
Enhanced oral activity response to A77636 in neonatal 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adamantane; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Benzopyrans; Dopamine Agents; Female; Injections, Intraperitoneal; Injections, Intraventricular; Male; Mouth; Oxidopamine; Pregnancy; Rats; Rats, Sprague-Dawley | 1994 |
Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.
Topics: Adamantane; Animals; Apomorphine; Benzazepines; Benzopyrans; Callithrix; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Quinpirole; Rotation | 2000 |
Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions.
Topics: Adamantane; Animals; Apomorphine; Autoradiography; Behavior, Animal; Benzazepines; Benzopyrans; Corpus Striatum; Denervation; Dopamine; Dopamine Agonists; Dopamine Antagonists; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Substantia Nigra; Subthalamic Nucleus; Sympatholytics | 2000 |
In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adamantane; Amidines; Animals; Antiparkinson Agents; Basal Ganglia; Denervation; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Microdialysis; Oxidopamine; Parkinsonian Disorders; Perfusion; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Time Factors | 2008 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2010 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra | 2011 |
Eppendorf finalist. Striatal interneurons: causes of or cures for movement disorders?
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Humans; Interneurons; Levodopa; Mice; Mice, Transgenic; Movement Disorders; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Receptors, AMPA; Receptors, Kainic Acid; Treatment Failure | 2012 |
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adamantane; Alternative Splicing; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Iodine Isotopes; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; RNA, Messenger; Sympatholytics | 2013 |
[Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats | 2014 |
Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats.
Topics: Adamantane; Animals; Behavior, Animal; Dipeptides; Disease Models, Animal; Dopaminergic Neurons; Male; Memory; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats, Wistar; Treatment Outcome | 2018 |